Biogen
PulseAugur coverage of Biogen — every cluster mentioning Biogen across labs, papers, and developer communities, ranked by signal.
3 day(s) with sentiment data
-
AI Enhances Antibody Design, But Lab Work Remains Crucial
Artificial intelligence has shown promise in enhancing the design of therapeutic antibodies, according to a recent study. While AI can improve existing drug candidates, the research emphasizes that traditional laborator…
-
AI superforecasting poised to transform FDA regulatory processes
AI superforecasting tools could revolutionize regulatory bodies like the FDA by providing objective predictions on project success and market viability. Currently, the FDA relies on subjective human judgment, leading to…
-
New two-step method simplifies antibody-drug conjugate creation for cancer therapies
Researchers have developed a novel two-step process for creating more uniform antibody-drug conjugates (ADCs). This method precisely attaches cancer drugs to a specific site on antibodies, streamlining the development o…
-
AI datacenter financing sparks 'debt bomb' fears, but experts say it's not Enron 2.0
Some experts are raising concerns about a potential "debt bomb" crisis due to large AI datacenter builders like Meta, Oracle, and CoreWeave financing construction through off-balance-sheet entities. This practice allows…
-
Experimental Alzheimer's drug diranersen shows promise targeting tau protein
An experimental Alzheimer's drug, diranersen, has shown promise in slowing cognitive decline by targeting the tau protein, a different approach than current amyloid-focused treatments. While the drug did not meet all it…
-
Autoimmune disease therapies boom amid VC investment; OpenAI targets healthcare
The field of autoimmune disease therapies is experiencing a significant boom, with projected revenues for drugs like AbbVie's Skyrizi expected to reach $33 billion by 2032. This growth is driven by scientific breakthrou…
-
AI model detects hidden multiple sclerosis lesions
A new artificial intelligence model has been developed that can identify previously invisible lesions associated with multiple sclerosis. This AI-driven approach promises to enhance diagnostic capabilities and potential…
-
Glass substrate tech gains market focus amid company R&D updates; Biogen eyes RayThera acquisition
The market is showing increased interest in glass substrate technology, spurred by TSMC's development plan. Several companies, including XingSen Technology, Medi-Tech, Vogue Optoelectronics, and Qibin Group, have announ…
-
Boston Scientific to acquire RayThera for up to $1B; SpaceX overtakes Amazon · 1 source tracked
Boston Scientific is set to acquire RayThera for up to $1 billion, a move aimed at expanding Boston Scientific's pipeline of investigational immunology products. The deal includes an upfront payment and additional payme…
-
New AI method boosts drug property prediction accuracy
Researchers have developed a new pretraining framework called Probabilistic Contrastive Pretraining (PCP) to enhance the prediction of ADME properties crucial for drug discovery. This method combines chemistry-specific …
-
Kordata Dynamics launches neurotech platform for clinical trials
Kordata Dynamics has launched to address a $26 billion market in central nervous system (CNS) therapeutics by integrating neurotechnology into clinical trials. The company, a spinout from BIOS Health, will partner with …
-
GNNs enhanced for drug discovery via ECFP pre-training
Researchers have developed a new strategy to enhance Graph Neural Networks (GNNs) for drug discovery tasks like Quantitative Structure-Activity Relationship (QSAR) studies. This method involves pre-training GNNs to pred…